BOSTON - PepGen Inc. (NASDAQ: PEPG), a biotechnology firm focused on oligonucleotide therapies for severe neuromuscular and neurological diseases, is progressing with its CONNECT clinical program for ...

Dyne Therapeutics is a clinical stage biotech concern with just over $700 million of cash on its balance sheet. Learn more ...

The FDA has granted fast track designation to DYNE-101, a therapy for myotonic dystrophy type 1 (DM1) now in testing in a ...

The FDA has granted fast-track designation to an investigational antisense oligonucleotide to treat individuals with myotonic ...

Oppenheimer reiterated its Outperform rating on Dyne Therapeutics (NASDAQ:DYN), maintaining a $60.00 price target, ...

Dyne Therapeutics, Inc. (NASDAQ: DYN) shares gained ground early Tuesday, a clinical-stage neuromuscular disease company focused on advancing life-transforming therapeutics for people living with ...

Company Anticipates Submitting for U.S. Accelerated Approval in H1 2026 - WALTHAM, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage neuromuscular diseas ...

Dyne Therapeutics (DYN) announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track designation for DYNE-101 for the ...

Company Anticipates Submitting for U.S. Accelerated Approval in H1 2026 - WALTHAM, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: DYN), a clinical-stage neuromuscular disease company focused on ...

We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to ...

DYNE-101 eased myotonia and led to other functional improvements for people with myotonic dystrophy type 1 (DM1) in a ...

Other symptoms may include: Often children with Becker muscular dystrophy can walk. As they get older they may need to use a cane or wheelchair to get around. The symptoms of myotonic dystrophy ...